Abstract:Emerging experimental evidence suggests that the spread of tau pathology in the brain in Tauopathies reflects the propagation of abnormal tau species along neuroanatomically connected brain areas. This propagation could occur through a “prion-like” mechanism involving transfer of abnormal tau seeds from a “donor cell” to a “recipient cell” and recruitment of normal tau in the latter to generate new tau seeds. This review critically appraises the evidence that the spread of tau pathology occurs via such a “prion-like” mechanism and proposes a number of recommendations for directing future research. Recommendations for definitions of frequently used terms in the tau field are presented in an attempt to clarify and standardize interpretation of research findings. Molecular and cellular factors affecting tau aggregation are briefly reviewed, as are potential contributions of physiological and pathological post-translational modifications of tau. Additionally, the experimental evidence for tau seeding and “prion-like” propagation of tau aggregation that has emerged from cellular assays and in vivo models is discussed. Propagation of tau pathology using “prion-like” mechanisms is expected to incorporate several steps including cellular uptake, templated seeding, secretion and intercellular transfer through synaptic and non-synaptic pathways. The experimental findings supporting each of these steps are reviewed. The clinical validity of these experimental findings is then debated by considering the supportive or contradictory findings from patient samples. Further, the role of physiological tau release in this scenario is examined because emerging data shows that tau is secreted but the physiological function (if any) of this secretion in the context of propagation of pathological tau seeds is unclear. Bona fide prions exhibit specific properties, including transmission from cell to cell, tissue to tissue and organism to organism. The propagation of tau pathology has so far not been shown to exhibit all of these steps and how this influences the debate of whether or not abnormal tau species can propagate in a “prion-like” manner is discussed. The exact nature of tau seeds responsible for propagation of tau pathology in human tauopathies remains controversial; it might be tightly linked to the existence of tau strains stably propagating peculiar patterns of neuropathological lesions, corresponding to the different patterns seen in human tauopathies. That this is a property shared by all seed-competent tau conformers is not yet firmly established. Further investigation is also required to clarify the relationship between propagation of tau aggregates and tau-induced toxicity. Genetic variants identified as risks factors for tauopathies might play a role in propagation of tau pathology, but many more studies are needed to document this. The contribution of selective vulnerability of neuronal populations, as an alternative to prion-like mechanisms to explain spreading of tau pathology needs to be clarified. Learning from the prion field will be helpful to enhance our understanding of propagation of tau pathology. Finally, development of better models is expected to answer some of these key questions and allow for the testing of propagation-centred therapies.

Possible Mechanisms of Tau Spread and Toxicity in Alzheimer’s Disease

Possible Mechanisms of Tau Spread and Toxicity in Alzheimer's Disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Spreading of Pathology in Alzheimer's Disease

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease

Study on interaction between microtubule associated protein tau and prion protein

The Sulfation Code of Tauopathies: Heparan Sulfate Proteoglycans in the Prion Like Spread of Tau Pathology

What is the evidence that tau pathology spreads through prion-like propagation?

Interaction Between A Beta And Tau In The Pathogenesis Of Alzheimer'S Disease

Role of the endolysosomal pathway and exosome release in tau propagation

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

Alzheimer’s disease brain-derived extracellular vesicles spread tau pathology in interneurons

Complicated Role of Post-translational Modification and Protease-Cleaved Fragments of Tau in Alzheimer’s Disease and Other Tauopathies

Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species

The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome

O3‐01‐05: in vitro measurements of tau aggregate elongation and fragmentation rates allow the modelling of prion‐like spreading in humans

Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy

Mechanistic Insights and Future Challenges

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

Tau Abnormalities and the Potential Therapy in Alzheimer’s Disease